Maculaitis et al. explored patient preferences for CDK4/6 inhibitor regimens for HR+ and HER2- advanced or MBC and found lowering the risk of diarrhea/severe diarrhea and Grade 3⁄4 neutropenia/serious infection were most important to both patients and HCPs (oncologists) [21]. This evidence concerns the gene CDK4 and infection.